$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000155905317000031 Filed on November 07, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$229.0K	$219.0K	$286.0K
YoY Change	33.92%	-23.43%	-33.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.04M	$12.44M	$16.14M
YoY Change	46.25%	-22.92%	173.1%
% of Gross Profit
Research & Development	$33.50M	$41.32M	$26.84M
YoY Change	-15.91%	53.94%	56.17%
% of Gross Profit
Depreciation & Amortization	$780.0K	$800.0K	$800.0K
YoY Change	-15.22%	0.0%	300.0%
% of Gross Profit
Operating Expenses	$47.55M	$53.75M	$42.97M
YoY Change	-3.85%	25.08%	86.12%
Operating Profit		-$53.53M	-$42.69M
YoY Change		25.41%	88.38%
Interest Expense	$90.00K	$120.0K	$140.0K
YoY Change	-40.0%	-14.29%	180.0%
% of Operating Profit
Other Income/Expense, Net	-$240.0K	-$565.0K	-$130.0K
YoY Change	-141.38%	334.62%	68.83%
Pretax Income	-$47.47M	-$54.10M	-$42.82M
YoY Change	-2.22%	26.35%	88.31%
Income Tax	$690.0K	-$1.705M	$421.0K
% Of Pretax Income
Net Earnings	-$47.76M	-$52.39M	-$43.24M
YoY Change	-2.34%	21.17%	88.19%
Net Earnings / Revenue	-20855.02%	-23924.2%	-15118.53%
Basic Earnings Per Share	-$1.24	-$1.37	-$1.26
Diluted Earnings Per Share	-$1.24	-$1.37	-$1.26
COMMON SHARES
Basic Shares Outstanding	38.45M shares	38.28M shares	34.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$417.6M	$456.1M	$408.6M
YoY Change	7.93%	11.63%	5.36%
Cash & Equivalents	$417.6M	$456.1M	$408.6M
Short-Term Investments
Other Short-Term Assets	$8.500M	$12.80M	$6.700M
YoY Change	97.67%	91.04%	34.0%
Inventory
Prepaid Expenses
Receivables	$240.0K	$220.0K	$409.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$426.3M	$469.1M	$415.6M
YoY Change	8.93%	12.85%	5.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$54.99M	$55.38M	$51.74M
YoY Change	-2.59%	7.05%	1665.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.843M	$2.784M	$2.162M
YoY Change	29.64%	28.77%	30785.71%
Total Long-Term Assets	$70.00M	$68.62M	$63.94M
YoY Change	2.02%	7.31%	1094.32%
TOTAL ASSETS
Total Short-Term Assets	$426.3M	$469.1M	$415.6M
Total Long-Term Assets	$70.00M	$68.62M	$63.94M
Total Assets	$496.3M	$537.7M	$479.6M
YoY Change	7.9%	12.11%	20.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.63M	$11.06M	$10.54M
YoY Change	4.32%	4.95%	159.73%
Accrued Expenses	$20.90M	$26.00M	$22.60M
YoY Change	-18.68%	15.04%	73.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$700.0K	$400.0K
YoY Change
Total Short-Term Liabilities	$37.37M	$39.26M	$36.91M
YoY Change	-9.02%	6.37%	98.88%
LONG-TERM LIABILITIES
Long-Term Debt	$51.50M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$52.20M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$51.77M	$52.17M	$41.57M
YoY Change	-3.23%	25.48%	1618.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.37M	$39.26M	$36.91M
Total Long-Term Liabilities	$51.77M	$52.17M	$41.57M
Total Liabilities	$89.14M	$91.43M	$78.48M
YoY Change	-5.74%	16.49%	274.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$442.4M	-$394.6M	-$240.3M
YoY Change	52.95%	64.2%	128.98%
Common Stock	$385.0K	$384.0K	$344.0K
YoY Change	10.63%	11.63%	9.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$407.2M	$446.3M	$401.1M
YoY Change
Total Liabilities & Shareholders Equity	$496.3M	$537.7M	$479.6M
YoY Change	7.9%	12.11%	20.22%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$47.76M	-$52.39M	-$43.24M
YoY Change	-2.34%	21.17%	88.19%
Depreciation, Depletion And Amortization	$780.0K	$800.0K	$800.0K
YoY Change	-15.22%	0.0%	300.0%
Cash From Operating Activities	-$39.52M	-$17.74M	-$29.76M
YoY Change	16.89%	-40.39%	75.99%
INVESTING ACTIVITIES
Capital Expenditures	-$380.0K	-$540.0K	-$8.560M
YoY Change	-94.68%	-93.69%	2493.94%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$4.060M
YoY Change		-100.0%
Cash From Investing Activities	-$370.0K	-$540.0K	-$4.500M
YoY Change	-94.82%	-88.0%	1263.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.460M	2.610M	3.950M
YoY Change	-92.44%	-33.92%	49.06%
NET CHANGE
Cash From Operating Activities	-39.52M	-17.74M	-29.76M
Cash From Investing Activities	-370.0K	-540.0K	-4.500M
Cash From Financing Activities	1.460M	2.610M	3.950M
Net Change In Cash	-38.43M	-15.67M	-30.31M
YoY Change	77.51%	-48.3%	107.75%
FREE CASH FLOW
Cash From Operating Activities	-$39.52M	-$17.74M	-$29.76M
Capital Expenditures	-$380.0K	-$540.0K	-$8.560M
Free Cash Flow	-$39.14M	-$17.20M	-$21.20M
YoY Change	46.76%	-18.87%	27.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	prta	Receivablefrom Option Exercises ReceivablefromOptionExercises	76000	USD
	prta	Receivablefrom Option Exercises ReceivablefromOptionExercises	1128000	USD
	prta	Buildto Suit Leases Increase Decreaseto Obligation BuildtoSuitLeasesIncreaseDecreasetoObligation	1805000	USD
CY2016Q4	prta	Buildto Suit Property Gross BuildtoSuitPropertyGross	51359000	USD
CY2017Q3	prta	Buildto Suit Property Gross BuildtoSuitPropertyGross	51760000	USD
CY2016Q4	prta	Buildtosuit Lease Obligation Current BuildtosuitLeaseObligationCurrent	0	USD
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
CY2017Q3	prta	Buildtosuit Lease Obligation Current BuildtosuitLeaseObligationCurrent	372000	USD
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38446761	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Prothena Corp plc
	dei	Trading Symbol TradingSymbol	PRTA
CY2016Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	19073000	USD
CY2017Q3	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	18482000	USD
	prta	Buildto Suit Leases Increase Decreaseto Obligation BuildtoSuitLeasesIncreaseDecreasetoObligation	0	USD
CY2017Q3	prta	Buildtosuit Lease Obligation Currentand Noncurrent BuildtosuitLeaseObligationCurrentandNoncurrent	52300000	USD
CY2016Q4	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	51320000	USD
CY2017Q3	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	51902000	USD
CY2017Q3	prta	Builtto Suit Leases At Cost BuilttoSuitLeasesAtCost	51800000	USD
	prta	Capitalized Interestunder Buildto Suit Transaction CapitalizedInterestunderBuildtoSuitTransaction	713000	USD
	prta	Capitalized Interestunder Buildto Suit Transaction CapitalizedInterestunderBuildtoSuitTransaction	0	USD
CY2016Q3	prta	Collaboration Revenue CollaborationRevenue	286000	USD
	prta	Collaboration Revenue CollaborationRevenue	884000	USD
CY2017Q3	prta	Collaboration Revenue CollaborationRevenue	219000	USD
	prta	Collaboration Revenue CollaborationRevenue	27290000	USD
CY2016Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2017Q3	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2016Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2017Q3	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2016Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2017Q3	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2016Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2017Q3	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2016Q4	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2017Q3	prta	Deferred Shares Value DeferredSharesValue	0	USD
	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	550000	USD
	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	2759000	USD
	prta	Noncash Investingand Financing Items Stock Option Shortfall NoncashInvestingandFinancingItemsStockOptionShortfall	18000	USD
	prta	Noncash Investingand Financing Items Stock Option Shortfall NoncashInvestingandFinancingItemsStockOptionShortfall	0	USD
	prta	Noncashamountcapitalizedunderbuildtosuittransaction Noncashamountcapitalizedunderbuildtosuittransaction	38584000	USD
	prta	Noncashamountcapitalizedunderbuildtosuittransaction Noncashamountcapitalizedunderbuildtosuittransaction	0	USD
	prta	Numberof Votes NumberofVotes	1	vote
CY2017Q3	prta	Purchaseand Contractual Obligation Due After Fifth Year PurchaseandContractualObligationDueAfterFifthYear	860000	USD
CY2017Q3	prta	Purchaseand Contractual Obligation Due Next Fiscal Year PurchaseandContractualObligationDueNextFiscalYear	19310000	USD
CY2017Q3	prta	Purchaseand Contractual Obligation Duein Fifth Year PurchaseandContractualObligationDueinFifthYear	100000	USD
CY2017Q3	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	100000	USD
CY2017Q3	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	7218000	USD
CY2017Q3	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	16195000	USD
CY2017Q3	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	43783000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2285000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	3250000	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	2096000	USD
CY2017Q3	prta	Sharebased Compensation Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationExcessTaxBenefitAmountBookedtoIncomeTaxProvision	2000000	USD
	prta	Sharebased Compensation Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationExcessTaxBenefitAmountBookedtoIncomeTaxProvision	5400000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13069000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	11062000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	840462000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	5000	USD
CY2016Q4	us-gaap	Assets Assets	459976000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	178000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	220000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	378000	USD
CY2017Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	53000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	98000	USD
CY2017Q3	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	0	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	435000	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	384000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7668000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6993000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	654266000	USD
CY2017Q3	us-gaap	Assets Assets	537680000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	391362000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	469064000	USD
CY2016Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	68614000	USD
CY2017Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	68616000	USD
CY2016Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	363000	USD
CY2017Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	987000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	386923000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	456061000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	370586000	USD
CY2016Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	412630000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	390979000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	460117000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	42044000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	69138000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34752116	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38443261	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34752116	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38443261	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	348000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	384000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-3156000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-479000	USD
CY2016Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	363000	USD
CY2017Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	49000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2080000	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	266000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	4077000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	5913000	USD
CY2017Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	6392000	USD
CY2016Q3	us-gaap	Depreciation Depreciation	800000	USD
	us-gaap	Depreciation Depreciation	1500000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	800000	USD
	us-gaap	Depreciation Depreciation	2300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1509000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	163000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.25
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.82
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6629000	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7509000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16136000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31452000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12438000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34182000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-42818000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-110414000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-54099000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-110132000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	421000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	791000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1705000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4653000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1557000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	294000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	11004000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3224000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-100000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	964000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	11183000	USD
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	138000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	405000	USD
CY2017Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	118000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-228000	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1600000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2769000	USD
CY2017Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	579000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	94573000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	91426000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	459976000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	537680000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41075000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	39258000	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	53498000	USD
CY2017Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	52168000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-52394000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-105479000	USD
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9629000	USD
CY2017Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9051000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	133985000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	163942000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9497000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3145000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82444000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-91659000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-43239000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-111205000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-130000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-156000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-565000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2195000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	42974000	USD
	us-gaap	Operating Expenses OperatingExpenses	111142000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	53753000	USD
	us-gaap	Operating Expenses OperatingExpenses	135227000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42688000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-110258000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-53534000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-107937000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1994000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	103000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	244000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	245000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	245000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	260000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	897000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2193000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2784000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8555000	USD
CY2017Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9289000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-268000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-561000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-683000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1967000	USD
CY2016Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1128000	USD
CY2017Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1347000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-2812000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	0	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	9497000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4261000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12783000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	128777000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150323000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	105000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2396000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15424000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64120000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62377000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56452000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55384000	USD
CY2017Q3	us-gaap	Purchase Obligation PurchaseObligation	41988000	USD
CY2017Q3	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2017Q3	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2017Q3	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2017Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	18835000	USD
CY2017Q3	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	7088000	USD
CY2017Q3	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	16065000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26838000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79690000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41315000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101045000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-289211000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-394592000	USD
CY2016Q3	us-gaap	Revenues Revenues	286000	USD
	us-gaap	Revenues Revenues	884000	USD
CY2017Q3	us-gaap	Revenues Revenues	219000	USD
	us-gaap	Revenues Revenues	27290000	USD
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	11448000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	19718000	USD
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	7102000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	19357000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	365403000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	446254000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34413000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34266000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38292000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37384000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment and Concentration of Risks</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivable from Roche as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> are amounts due from Roche entities located in the U.S. and Switzerland under the License Agreement that became effective January 22, 2014. Revenue recorded in the Statements of Operations consists of reimbursement from Roche for research and development services. Credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$54.7 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$55.7 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates, including for commercial supplies if the Company obtains regulatory approval to market any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all pre-clinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future, including for commercial supplies if the Company obtains regulatory approval to market any of its drug candidates. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation and research and development expenses. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001559053-17-000031-index-headers.html	Edgar Link	pending
0001559053-17-000031-index.html	Edgar Link	pending
0001559053-17-000031.txt	Edgar Link	pending
0001559053-17-000031-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
prta-20170930.xml	Edgar Link	completed
prta-20170930.xsd	Edgar Link	pending
prta-20170930_cal.xml	Edgar Link	unprocessable
prta-20170930_def.xml	Edgar Link	unprocessable
prta-20170930_lab.xml	Edgar Link	unprocessable
prta-20170930_pre.xml	Edgar Link	unprocessable
prta2017q310-q.htm	Edgar Link	pending
prta2017q310-qxex311.htm	Edgar Link	pending
prta2017q310-qxex312.htm	Edgar Link	pending
prta2017q310-qxex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2017 Q4 Form 10-Q Financial Statement

#000155905317000031 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2017 Q4 Form 10-Q Financial Statement

#000155905317000031 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta